I am hoping for some more safety data from the XP or CVA trials. An announcement for the new healthy volunteer trial commencing mid 25 would also be welcome news.
Truth is Wolgen never wanted the buyback, he lied to us at the results webinar and he has Rosenfeld’s full support.
Clinuvel the only company incapable of executing a buy back. Was the EU rollout failure related to systemic failings seen in all aspects of their business? When will someone hold Wolgen to account?
I am hoping for some more safety data from the XP or CVA trials....
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.83 |
Change
0.310(2.13%) |
Mkt cap ! $735.1M | |||
| Open | High | Low | Value | Volume |
| $14.57 | $14.88 | $14.52 | $512.9K | 34.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13 | $14.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.85 | 180 | 3 |
View Market Depth
| Last trade - 11.52am 02/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |